[1] |
Effiom OA, Ogundana OM, Akinshipo AO , et al. Ameloblastoma: current etiopathological concepts and management[J]. Oral Dis, 2018,24(3):307-316.
DOI
URL
|
[2] |
Pindborg JJ, Kramer JR, Torloni H . Histological typing of odontogenic tumours, jaw cysts and allied lesions[M]. Geneva: WHO, 1971.
|
[3] |
Kramer IRH, Pindborg JJ, Shear M , et al. WHO international histological classification of tumours. Histological typing of odontogenic tumours[M]. Heidelberg: Springer-Verlag, 1992.
|
[4] |
Barnes L, Eveson JW, Reichart PA , et al. World Health Organization classification of tumours: pathology and genetics of tumours of the head and neck[M]. Lyon: IARC, 2005.
|
[5] |
El-Naggar AK, Chan JKC, Grandis JR , et al. WHO classification of head and neck tumours[M]. Lyon, France: IARC, 2017.
|
[6] |
Wright JM, Vered M . Update from the 4th edition of the World Health Organization classification of head and neck tumours: odontogenic and maxillofacial bone tumors[J]. Head and Neck Pathology, 2017,11(1):68-77.
|
[7] |
陶谦, 梁培盛 . 2017版WHO牙源性肿瘤新分类之述评[J]. 口腔疾病防治, 2018,25(12):749-754.
|
|
Tao Q, Liang PS . A review of new WHO classification of odontogenic tumors in 2017[J]. J Prev Treat Stomatol Dis, 2018,25(12):749-754.
|
[8] |
Ruslin M, Hendra FN, Vojdani A , et al. The Epidemiology, treatment, and complication of ameloblastoma in East-Indonesia: 6 years retrospective study[J]. Med Oral Patol Oral Cir Bucal, 2018,23(1):e54-e58.
|
[9] |
Saghravanian N, Salehinejad J, Ghazi N , et al. A 40-year retrospective clinicopathological study of ameloblastoma in Iran[J]. Asian Pac J Cancer Prev, 2016,17(2):619-623.
DOI
URL
|
[10] |
Wright JM, Odell EW, Speight PM , et al. Odontogenic tumors, WHO 2005: where do we go from here?[J]. Head Neck Pathol, 2014,8(4):373-382.
|
[11] |
Speight PM, Takata T . New tumour entities in the 4th edition of the World Health Organization classification of head and neck tumours: odontogenic and maxillofacial bone tumours[J]. Virchows Arch, 2018,472(3):331-339.
DOI
URL
|
[12] |
Anand R, Sarode GS, Sarode SC , et al. Clinicopathological characteristics of desmoplastic ameloblastoma: a systematic review[J]. J Investig Clin Dent, 2018,9(1):e12282.
|
[13] |
Saluja TS, Hosalkar R . Reconnoitre ameloblastic carcinoma: a prognostic update[J]. Oral Oncol, 2018,77:118-124.
DOI
URL
|
[14] |
Siriwardena BSMS, Tennakoon TMPB, Hunter KD , et al. Unicystic ameloblastoma: analysis of 370 cases in a single center in Sri Lanka[J]. J Oral Pathol Med, 2018,47(7):706-709.
DOI
URL
|
[15] |
Ganjre AP, Sarode G, Sarode S . Molecular characterization of metastasizing ameloblastoma: a comprehensive review[J]. J Cancer Res Ther, 2019,15(3):455-462.
DOI
URL
|
[16] |
Dissanayake RK1, Jayasooriya PR, Siriwardena DJ , et al. Review of metastasizing (malignant) ameloblastoma (METAM): pattern of metastasis and treatment[J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2011,111(6):734-741.
DOI
URL
|
[17] |
Kurppa KF, Caton J, Morgan PR , et al. High frequency of BRAF V600E mutations in ameloblastoma[J]. J Pathol, 2014,232(5):492-498.
DOI
URL
|
[18] |
Sweeney RT, McClary AC, Myers BR , et al. Identifcation of recurrent SMO and BRAF mutations in ameloblastomas[J]. Nat Genet, 2014,46(7):722-725.
DOI
URL
|
[19] |
Brown NA, Rolland D, McHugh JB , et al. Activating FGFR2-RAS-BRAF mutations in ameloblastoma[J]. Clin Cancer Res, 2014,20(21):5517-5526.
DOI
URL
|
[20] |
Fregnani ER, Perez DE, Paes de Almeida O , et al. BRAF-V600E expression correlates with ameloblastoma aggressiveness[J]. Histopathology, 2017,70(3):473-484.
|
[21] |
Soltani M, Tabatabaiefar MA, Mohsenifar Z , et al. Genetic study of the BRAF gene reveals new variants and high frequency of the V600E mutation among Iranian ameloblastoma patients[J]. J Oral Pathol Med, 2018,47(1):86-90.
DOI
URL
|
[22] |
Kelppe J, Thorén H, Ristimäki A , et al. BRAF V600E expression in ameloblastomas--a 36-patient cohort from Helsinki University Hospital[J]. Oral Dis, 2019,25(4):1169-1174.
DOI
URL
|
[23] |
Chapman PB, Hauschild A, Robert C , et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation[J]. N Engl J Med, 2011,364(26):2507-2516.
DOI
URL
|
[24] |
Planchard D, Smit EF, Groen HJM , et al. Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial[J]. Lancet Oncol, 2017,18(10):1307-1316.
DOI
URL
|
[25] |
Kaye FJ, Ivey AM, Drane WE , et al. Clinical and radiographic response with combined BRAF targeted therapy in stage 4 ameloblastoma[J]. J Natl Cancer Inst, 2014,107(1):378.
|
[26] |
Tan S, Pollack JR, Kaplan MJ , et al. BRAF inhibitor treatment of primary BRAF-mutant ameloblastoma with pathologic assessment of response[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2016,122(1):e5-e7.
|
[27] |
Faden DL, Algazi A . Durable treatment of ameloblastoma with single agent BRAFi Re: clinical and radiographic response with combined BRAF-targeted therapy in stage 4 ameloblastoma[J]. J Natl Cancer Inst, 2017,109(1). doi: 10. 1093/jnci/djw190.
|
[28] |
Fernandes GS, Girardi DM, Bernardes JPG , et al. Clinical benefit and radiological response with BRAF inhibitor in a patient with recurrent ameloblastoma harboring V600E mutation[J]. BMC Cancer, 2018,18(1):887.
DOI
URL
|
[29] |
Neagu D, Escuder-de la Torre O, Vázquez-Mahía I , et al. Surgical management of ameloblastoma. Review of literature[J]. J Clin Exp Dent, 2019,11(1):e70-e75.
|
[30] |
Gawande PD, Khande K, Agrawal G . Ameloblastic carcinoma: a rare malignant tumour in maxillofacial region[J]. J Maxillofac Oral Surg, 2017,16(3):377-381.
DOI
URL
|